Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this study, researchers found that in mouse models of alopecia areata, the expression of immune-regulating molecules PD-L1 and PD-L2 in dermal fibroblasts is increased by activated T cells, potentially indicating a lack of negative immune control in affected skin.

This study observed that oral tofacitinib was effective and safe for treating alopecia areata in paediatric patients, with 82% of pre-adolescent participants experiencing hair regrowth and 64% showing significant improvement in their hair loss severity scores.

This study found that patients with alopecia areata receiving ritlecitinib showed immune responses to meningococcal and tetanus vaccines, achieving significant antibody levels after vaccination, and no vaccine-related adverse events or disease exacerbations were reported despite a small sample size.

This notice corrects an article on fluridil for androgenetic alopecia, indicating potential conflicts of interest due to the authors' patent holdings and funding source; it reports no new research findings.

This study suggests that hypersensitivity and increased serum IgE levels might contribute to the pathogenesis of diffuse alopecia areata through intense local inflammatory infiltration.

This research aims to address gaps in understanding alopecia areata by evaluating the real-world effectiveness and safety of baricitinib, identifying predictors of therapeutic response, and exploring the long-term impact on life quality, including sexual health. Results are not reported in the abstract.

This case report suggests acitretin as a potential treatment for pseudoainhum, following the successful resolution of the condition in a patient with palmoplantar keratoderma and congenital alopecia.

This source describes a previous case report that combined anthralin and calcipotriene to treat alopecia areata, showing promising results, but highlights that further research is needed to understand the mechanisms and potential benefits of this combination therapy.

This study observed that acute diffuse and total alopecia, a subtype of alopecia areata, typically resolves rapidly and spontaneously within about six months, even without treatment, suggesting a favorable prognosis.

JAK inhibitors improve hair growth in alopecia areata, especially in patchy types.

This study found that JAK inhibitor treatment in patients with alopecia areata was associated with a lower incidence of major depressive disorder and decreased antidepressant usage.

This study evaluated eight JAK inhibitor regimens for alopecia areata and provided high-quality evidence on their comparative effectiveness, which can aid clinicians in decision-making and inform medical practice guidelines.

This case report highlights the successful treatment of a 37-year-old male with steroid-resistant beard alopecia areata using baricitinib, a JAK-1/2 inhibitor, over 9 months, resulting in reduced hair loss and improved hair density.

Children with alopecia areata should only get thyroid screening if they have Down syndrome, a family history of thyroid disease, atopy, or signs of thyroid problems.

Dupilumab may help treat alopecia areata, but more research is needed.

This study found that topical immunotherapy affects angiogenesis and immune cell ratios in the scalp, potentially offering insights into the mechanisms underlying alopecia areata.

This study presents case reports of four patients with alopecia areata or alopecia universalis, highlighting varied responses to treatments like prednisone, intralesional triamcinolone, and squaric acid dibutyl ester.

This review discusses recent therapeutic approaches for alopecia areata, including the use of Janus kinase inhibitors and interleukin-2, and reports no new clinical results.

This study found that topical Dithranol 0.5% is more effective than topical Tacrolimus 0.1% for hair regrowth in patients with alopecia areata, with 40% of Dithranol-treated patients showing over 80% hair regrowth compared to 23.33% for Tacrolimus-treated patients.

In this study, replacing the original pin with a different one on a larger cupola improved pseudo alopecia areata lesions in 58.8% of patients.

This study found that in alopecia areata, treatment with the oral JAK-inhibitor tofacitinib decreased clonally expanded CD8⁺ T cells in the scalp, but many expanded clones did not completely disappear, potentially leading to relapse after stopping treatment.

This study suggests that targeting mitophagy to regulate mitochondrial dysfunction and inhibit inflammasome activation could offer a novel therapeutic approach for alopecia areata.

This review identified evidence gaps in NHIRD, emphasizing the lack of validated diagnostic criteria and the need for further research on ocular and systemic comorbidities associated with AA to enhance patient care and treatment strategies.

This study found that Israeli patients with alopecia areata had a higher prevalence of comorbid conditions, including food allergies and chronic spontaneous urticaria, compared to matched controls.

This review discusses JAK inhibitors as promising new treatments for various chronic dermatologic conditions, including some recent drug approvals, and reports no new clinical results.

This historical observation found that parathyroid extract treatment in newborn rats led to a condition resembling scleroderma, characterized by skin hardening, calcium deposition, and possible necrosis.

This review discusses squaric acid dibutylester's use, effects, and safety in treating alopecia areata, but reports no new clinical results.

This study found that among adolescents with alopecia areata and significant hair loss, treatment with ritlecitinib resulted in greater hair regrowth and self-reported improvement compared to placebo over 48 weeks, with common side effects including headache, acne, and nasopharyngitis.

This study found that plasmacytoid dendritic cells may initiate alopecia areata in mice by overexpressing interferon-alpha.